Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Regeneron Pharmaceuticals Inc (REGN)  
$985.02 4.45 (0.45%) as of 4:30 Fri 5/24


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 104,690,000
Market Cap: 103.12(B)
Last Volume: 259,279 Avg Vol: 765,410
52 Week Range: $692.45 - $993.95
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:

    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  150
Guru Rank Value     : 6.9
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 168,566 236,471 279,472 438,206
Total Sell Value $164,437,486 $226,505,895 $262,153,799 $373,147,368
Total People Sold 8 14 16 18
Total Sell Transactions 15 42 60 120
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 2414
  Page 8 of 97  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Mccourt Marion EVP Commercial   •       –      –    2023-06-01 4 AS $736.00 $184,000 D/D (250) 20,553 14%     
   Ryan Arthur F Director   –       •      –    2023-06-01 4 AS $730.03 $73,542 D/D (100) 18,847 14%     
   Schleifer Leonard S President & CEO   •       •      –    2023-05-15 4 GA $0.00 $0 I/I 53,807 64,985     -
   Schleifer Leonard S President & CEO   •       •      –    2023-05-15 4 GD $0.00 $0 I/I 53,807 0     -
   Murphy Andrew J EVP Research   •       –      –    2023-05-09 4 GD $0.00 $0 D/D 1,326 59,421     -
   Ryan Arthur F Director   –       •      –    2023-05-01 4 AS $802.67 $80,533 D/D (100) 18,947 3%     
   Brown Michael S Director   –       •      –    2023-04-21 4 AS $798.42 $2,451,149 D/D (3,070) 1,247 4%     
   Brown Michael S Director   –       •      –    2023-04-21 4 OE $520.01 $1,596,431 D/D 3,070 4,317     -
   Ryan Arthur F Director   –       •      –    2023-04-03 4 AS $816.58 $81,931 D/D (100) 19,047 -2%     
   Vagelos P Roy Director   –       •      –    2023-04-03 4 GD $0.00 $0 I/I 259 125,493     -
   Mccourt Marion EVP Commercial   •       –      –    2023-04-03 4 AS $818.80 $900,680 D/D (1,100) 20,803 -2%     
   Mccourt Marion EVP Commercial   •       –      –    2023-04-03 4 OE $372.46 $409,706 D/D 1,100 21,903     -
   Landry Robert E EVP Finance CFO   •       –      –    2023-03-28 4 AS $818.81 $829,233 D/D (1,007) 31,922 -6%     
   Landry Robert E EVP Finance CFO   •       –      –    2023-03-27 4 AS $819.47 $150,372 D/D (183) 32,929 -7%     
   Landry Robert E EVP Finance CFO   •       –      –    2023-03-27 4 D $825.17 $2,304,700 D/D (2,793) 33,112     -
   Landry Robert E EVP Finance CFO   •       –      –    2023-03-27 4 OE $378.98 $1,442,476 D/D 3,800 35,316     -
   Bassler Bonnie L Director   –       •      –    2023-03-24 4 AS $818.00 $1,014,320 D/D (1,240) 1,247 -6%     
   Bassler Bonnie L Director   –       •      –    2023-03-24 4 OE $380.95 $472,378 D/D 1,240 2,487     -
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2023-03-23 4 D $801.59 $5,404,320 D/D (6,742) 27,471     -
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2023-03-23 4 OE $270.43 $2,704,300 D/D 10,000 34,213     -
   Yancopoulos George President and Chief Scientific   •       •      –    2023-03-23 4 AS $800.59 $2,940,374 I/I (3,656) 196,848 -9%     
   Vagelos P Roy Director   –       •      –    2023-03-23 4 GD $0.00 $0 D/D 25,000 312,578     -
   Fenimore Christopher R. SVP Controller   •       –      –    2023-03-23 4 AS $806.47 $1,767,782 D/D (2,192) 18,409 -9%     
   Larosa Joseph J EVP General Counsel and Secret   •       –      –    2023-03-10 4 GD $0.00 $0 I/I 1,006 0     -
   Mccourt Marion EVP Commercial   •       –      –    2023-03-01 4 AS $759.89 $835,879 D/D (1,100) 20,803 -7%     

  2414 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 8 of 97
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed